
## Magalie Dosset

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4086448/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells. Nature Immunology, 2014, 15, 758-766.	14.5	187
2	PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. Oncolmmunology, 2018, 7, e1433981.	4.6	167
3	Analysis of Spontaneous Tumor-Specific CD4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response. Clinical Cancer Research, 2012, 18, 2943-2953.	7.0	97
4	Selective degradation of PU.1 during autophagy represses the differentiation and antitumour activity of TH9 cells. Nature Communications, 2017, 8, 559.	12.8	67
5	Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer. British Journal of Cancer, 2019, 121, 405-416.	6.4	63
6	Cleaved Caspase-3 Transcriptionally Regulates Angiogenesis-Promoting Chemotherapy Resistance. Cancer Research, 2019, 79, 5958-5970.	0.9	55
7	Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor. Clinical Cancer Research, 2012, 18, 6284-6295.	7.0	54
8	Immunoregulation and Clinical Implications of ANGPT2/TIE2+ M-MDSC Signature in Non–Small Cell Lung Cancer. Cancer Immunology Research, 2020, 8, 268-279.	3.4	31
9	Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo. Blood, 2010, 115, 3025-3032.	1.4	30
10	The Angiogenic Growth Factor and Biomarker Midkine Is a Tumor-Shared Antigen. Journal of Immunology, 2010, 185, 418-423.	0.8	30
11	Immunogenicity Evaluation of a Rationally Designed Polytope Construct Encoding HLA-A*0201 Restricted Epitopes Derived from Leishmania major Related Proteins in HLA-A2/DR1 Transgenic Mice: Steps toward Polytope Vaccine. PLoS ONE, 2014, 9, e108848.	2.5	28
12	Circulating NKp46 <sup>+</sup> Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung Cancer. OncoImmunology, 2019, 8, e1527498.	4.6	28
13	The unfolded protein response links tumor aneuploidy to local immune dysregulation. EMBO Reports, 2021, 22, e52509.	4.5	22
14	lmmunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4 <sup>+</sup> Th1 responses against telomerase in cancer patients. Oncolmmunology, 2016, 5, e1137416.	4.6	21
15	Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine. Human Vaccines and Immunotherapeutics, 2013, 9, 1073-1077.	3.3	20
16	Telomerase and CD4 T Cell Immunity in Cancer. Cancers, 2020, 12, 1687.	3.7	20
17	Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination. Oncolmmunology, 2013, 2, e23430.	4.6	17
18	ls preexisting antitumor CD4 T cell response indispensable for the chemotherapy induced immune regression of cancer?. Oncolmmunology, 2012, 1, 1617-1619.	4.6	11

MAGALIE DOSSET

#	Article	IF	CITATIONS
19	The Unfolded Protein Response at the Tumor-Immune Interface. Frontiers in Immunology, 2022, 13, 823157.	4.8	11
20	lmmunogenicity of a recombinant lentiviral vector carrying human telomerase tumor antigen in HLA-B*0702 transgenic mice. Vaccine, 2010, 28, 6374-6381.	3.8	10
21	Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors. Cells, 2020, 9, 1727.	4.1	8
22	Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment. Oncotarget, 2018, 9, 35394-35407.	1.8	6
23	Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic mice. Oncotarget, 2017, 8, 48959-48971.	1.8	5
24	Disulfiram's journey from rubber vulcanization to Tâ $\in \!\! {f c}$ ell activation. EMBO Journal, 0, , .	7.8	0